Skip to main content

Table 3 Outcomes of patients in each study group

From: Rapidly improving acute respiratory distress syndrome in COVID-19: a multi-centre observational study

 

All

(n = 280)

Rapidly improving ARDS group (n = 11)

Intermediate

group (n = 235)

Persistent severe ARDS group (n = 34)

p value

Usage of vasopressors, n (%)

275 (99.3)

11 (100.0)

230 (99.1)

34 (100.0)

1.0

Vasopressor-free days, days

0.0 (0.0–12.0)

4.0 (1.0–24.0)

0.0 (0.0–14.3)

0.0 (0.0–0.0)

 < 0.001b,c

Usage of continuous renal replacement therapy, n (%)

114 (41.2)

4 (36.4)

99 (42.7)

11 (32.4)

0.493

Continuous renal replacement therapy-free days, days

18.0 (6.0–28.0)

25.0 (6.0–28.0)

20.0 (8.0–28.0)

4.0 (2.8–10.3)

 < 0.001b,c

Duration of mechanical ventilation among survivors, days

18.0 (8.3–34.8)

3.0 (2.3–5.3)

19.0 (9.0–35.5)

29.5 (10.0–34.5)

0.11

Ventilator-free days, days

0.0 (0.0–6.5)

0.0 (0.0–25.0)

0.0 (0.0–10.0)

0.0 (0.0–0.0)

0.011b,c

ICU-free days, days

0.0 (0.0–0.0)

0.0 (0.0–22.0)

0.0 (0.0–3.5)

0.0 (0.0–0.0)

0.016b,c

ICU-mortality, n (%)

147 (52.5)

6 (54.5)

113 (48.1)

28 (82.4)

0.001b,c

  1. Data are presented as median (interquartile range) of number of patients (%)
  2. Intermediate group includes two patients from Crete, who were transferred to another ICU on the 5th and 9th day following intubation, respectively. These patients were considered alive at day 28 following intubation. Persistent severe ARDS group includes 10 patients who were not alive on the second day following intubation
  3. Outcomes other than duration of mechanical ventilation were censored at day 28 following intubation. Patients discharged from ICU with unassisted breathing before 28 days considered to be alive at 28 days without needing vasopressors or continuous renal replacement therapy. Vasopressor-free days, continuous renal replacement therapy-free days, ventilator-free days and ICU-free days were calculated by the number of days in the first 28 days following intubation that a patient was alive and not receiving vasopressors, not receiving continuous renal replacement therapy, not on a ventilator or not in the ICU, respectively
  4. ICU-mortality was 42.4% (14 of 33) for patients with mild ARDS, 50.7% (76 of 150) for patients with moderate ARDS and 58.3% (56 of 96) for those with severe ARDS on the day of intubation
  5. n number, ARDS acute respiratory distress syndrome, ICU intensive care unit
  6. aDenotes statistical significance for the comparison between “rapidly improving ARDS” and “intermediate” groups
  7. bDenotes statistical significance for the comparison between “rapidly improving ARDS” and “persistent severe ARDS” groups
  8. cDenotes statistical significance for the comparison between “intermediate” and “persistent severe ARDS” groups
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us